Clinical Trial Update: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating SHR-1701 plus platinum-containing chemotherapy, with or without Bevacizumab (BP102), as first-line treatment for cervical cancer has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• SHR-1701

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Cervical Cancer | Phase 3 | Status: TERMINATED